VERAXA Biotech (NASDAQ: VRXA) began trading on the Nasdaq Capital Market on June 11, 2026, following the successful conclusion of a business combination with Voyager Acquisition Corp. The company is advancing a diversified oncology pipeline that spans monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific ADCs, and its proprietary BiTAC-based therapeutic formats across multiple cancer indications.
VERAXA's proprietary BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, with the goal of improving target specificity while reducing off-tumor toxicity. Through its focus on ADCs and T-cell engagers (TCEs), VERAXA is positioned within two rapidly growing segments of the global oncology therapeutics market.
Via selected partnerships, VERAXA aims to contribute value to developments in complementary therapeutic sectors such as radioimmunoconjugates (RICs) and antibody-oligonucleotide conjugates (AOCs). The company's vision is to deliver the next wave of smart cancer therapies with curative potential for solid tumors.
As a newly public company, VERAXA faces risks common to early-stage biotech firms, including those detailed in its SEC filings. The company's ability to execute on its pipeline and partnerships will be critical to its success. For more information, see full terms of use and disclaimers on the InvestorBrandNetwork website: http://IBN.fm/Disclaimer.